BRENZAVVY

PeakSM

bexagliflozin

NDAORALTABLET

Approved

Jan 2023

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

Sodium-Glucose Transporter 2 Inhibitors

Pharmacologic Class:

Sodium-Glucose Cotransporter 2 Inhibitor

Indications (2)

type 2 diabetes mellitus type 1 diabetes mellitus

Loss of Exclusivity

LOE Date

May 14, 2032

75 months away

Patent Expiry

May 14, 2032

Exclusivity Expiry

Jan 20, 2028

Patent Records (5)

Patent #	Expiry	Type	Use Code
8106021	Aug 22, 2028		U-2214
8802637	Aug 22, 2028	SubstanceProduct	U-2214
7838499	Jan 30, 2029	SubstanceProduct	U-2214
10981942	Jun 13, 2031	SubstanceProduct	—
10533032	Jul 3, 2031		U-2214

Company

MA - Marlborough

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers